Dynavax Technologies Corporation
DVAXDrugs in Pipeline
8
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Q1 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
HEPLISAV-B
Chronic Kidney Disease
HEPLISAV
Hepatitis B
Engerix-B
Hepatitis B
Fendrix
End Stage Renal Disease
Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate
Rhinitis, Allergic, Seasonal
Z-1018
Shingles
rF1V-1018
Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis
rF1V vaccine
Plague, Pneumonic
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HEPLISAV-B | Phase 3 | Chronic Kidney Disease | - | - |
HEPLISAV | Phase 3 | Hepatitis B | - | - |
Engerix-B | Phase 3 | Hepatitis B | - | - |
Fendrix | Phase 3 | End Stage Renal Disease | - | - |
Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate | Phase 2 | Rhinitis, Allergic, Seasonal | - | - |
Z-1018 | Phase 2 | Shingles | - | - |
rF1V-1018 | Phase 2 | Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis | - | - |
rF1V vaccine | Phase 2 | Plague, Pneumonic | - | - |
Hepatitis B
2 drugs in this indication
Rhinitis, Allergic, Seasonal
1 drug in this indication
Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis
1 drug in this indication
Plague, Pneumonic
1 drug in this indication
End Stage Renal Disease
1 drug in this indication
Shingles
1 drug in this indication
Chronic Kidney Disease
1 drug in this indication
Healthy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Dynavax Technologies Corporation's drug pipeline?→
CatalystAlert tracks 8 drug candidates in Dynavax Technologies Corporation's (DVAX) pipeline across Phase 3, Phase 2. Its lead program is HEPLISAV-B (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Dynavax Technologies Corporation's next FDA catalyst?→
Dynavax Technologies Corporation's (DVAX) next tracked catalyst is a Phase 2 expected January 29, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DVAX biotech catalysts?→
Add DVAX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Dynavax Technologies Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.